Mycobacterial infection and the impact of rifabutin treatment in organ transplant recipients: A single-center study.

In this study, the impact of rifabutin treatment on organ transplant recipients with TB infection was evaluated with respect to the trend of infection, management and outcome. The medical records of 26 post-transplant patients who received an organ transplant between 2004 and 2012 and later diagnosed with TB of different organs were reviewed retrospectively. We retrieved data regarding clinical features as well as treatment and outcomes. The median time interval between transplantation and TB was 36 months (IQR 12-101 months). The most common form of infection was pulmonary/pleural TB. All our subjects received rifabutin instead of rifampin in the anti-TB treatment regime as rifabutin is a less-potent inducer of cytochrome P-450. All patients responded satisfactorily to the treatment and maintained excellent allograft function. Moreover, we did not have any mortality among our recipients. Drug-induced hepatitis was observed in nine (35%) patients. Rifabutin is an excellent alternative medication to rifampin in the setting of TB management. Hepatotoxicity is a potential risk for treatment because of the potential additive toxicity of immunosuppressive drugs. PMID: 25579709 [PubMed - in process]
Source: Saudi Journal of Kidney Diseases and Transplantation - Category: Urology & Nephrology Authors: Tags: Saudi J Kidney Dis Transpl Source Type: research

Related Links:

Publication date: Available online 20 October 2019Source: Best Practice &Research Clinical HaematologyAuthor(s): Richard J. JonesAbstractClose HLA matching of donors and recipients has been the dogma for successful allogeneic blood or marrow transplantation (BMT), to limit the complications of graft rejection and graft-versus-host disease (GVHD). However, many patients in need, especially those in certain racial and ethnic groups such as African-Americans and Hispanics, are unable to find matches despite increased availability of unrelated donors. Unfortunately, despite many early attempts to develop safe, related hapl...
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research
Publication date: Available online 20 October 2019Source: British Journal of Oral and Maxillofacial SurgeryAuthor(s): R. Sacco, S. Shah, R. Leeson, V. Moraschini, C.F. de Almeida Barros Mourão, O. Akintola, A. LalliAbstractTumour necrosis factor-α (TNF-α) inhibitors are increasingly being used as immunomodulators to manage inflammatory conditions such as rheumatoid arthritis and Crohn’s disease. Reported serious side effects include an increased incidence of lymphoma and greater susceptibility to infections such as tuberculosis. The aim of this systematic review was to find out whether there is an ...
Source: British Journal of Oral and Maxillofacial Surgery - Category: ENT & OMF Source Type: research
Publication date: Available online 20 October 2019Source: BurnsAuthor(s): Luiz Philipe Molina Vana, Cláudia Naves Battlehner, Marcelo Alves Ferreira, Elia Garcia Caldini, Rolf Gemperli, Nivaldo AlonsoAbstractThe advent of dermal regeneration templates has fostered major advances in the treatment of acute burns and their sequelae, in the last three decades. Both data on morphological aspects of the newly-formed tissue, and clinical trials comparing different templates, are few. The goal of this study was to prospectively analyze the outcome of randomized patients treated with two of the existing templates, followed b...
Source: Burns - Category: Dermatology Source Type: research
Condition:   Transplant; Decision-making Interventions:   Other: Total Survival;   Other: Stratified Transplant Survival Sponsor:   Carnegie Mellon University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Ridge Preservation Interventions:   Procedure: Ridge preservation using L-PRF/FDBA layered technique;   Procedure: Ridge preservation using L-PRF/FDBA;   Procedure: Ridge preservation using L-PRF Sponsor:   University of Alabama at Birmingham Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Hepatitis B, Chronic Interventions:   Drug: Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibody;   Drug: Nucleoside/nucleotide analogues Sponsor:   Henlix, Inc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Discussion Transplantation is not a common problem for primary care physicians but when a child’s disease has progressed to end-stage organ failure, transplantation can be the only treatment available. While the primary care provider usually is not involved in the daily management of patients before, during and after transplantation, they can be involved in many areas. These can include providing appropriate primary and acute care, ordering and obtaining necessary medical tests, medications and equipment, assisting with medical insurance, providing medical history and records to consultants, translating medical infor...
Source: PediatricEducation.org - Category: Pediatrics Authors: Tags: Uncategorized Source Type: news
Discussion MDSCs violently emerge in pathological conditions in an attempt to limit potentially harmful immune and inflammatory responses. Mechanisms supporting their expansion and survival are deeply investigated in cancer, in the perspective to reactivate specific antitumor responses and prevent their contribution to disease evolution. These findings will likely contribute to improve the targeting of MDSCs in anticancer immunotherapies, either alone or in combination with immune checkpoint inhibitors. New evidence indicates that the expansion of myeloid cell differentiation in pathology is subject to fine-tuning, as its...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
We report an unusual case of GBS in a hepatitis C virus-positive hemodialysis (HD)-dependent patient who was being treated with sofosbuvir and daclatasvir along with antitubercular drugs for pulmonary tuberculosis. One should keep GBS in the differential diagnosis in HD patients whenever patient presents with lower limb weakness. Early diagnosis will help in timely initiation of treatment which is crucial to treat GBS. PMID: 30381528 [PubMed - in process]
Source: Saudi Journal of Kidney Diseases and Transplantation - Category: Urology & Nephrology Authors: Tags: Saudi J Kidney Dis Transpl Source Type: research
This article does not contain any studies with human participants or animals performed by the author. Data Availability All national (MagIran, Science Information Database (SID) and Iranmedex) and international (PubMed, Scopus) databases were searched from November 2010 to November 2016 using keywords both in English and Persian: Afghan immigrants, Afghan refugees, Iran, infectious diseases, tuberculosis, HIV, Hepatitis B and C, non-communicable disease, food security, mental health, barriers, health insurance, access to health service. All related websites and webpages were also searched by Google with the same keywords ...
Source: PLOS Currents Disasters - Category: International Medicine & Public Health Authors: Source Type: research
More News: Bone Graft | Hepatitis | Kidney Transplant | Kidney Transplantation | Middle East Health | Study | Toxicology | Transplant Surgery | Transplants | Tuberculosis | Urology & Nephrology